Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-25-000649
Filing Date
2025-02-28
Accepted
2025-02-28 16:46:36
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 18517
  Complete submission text file 0000921895-25-000649.txt   20131
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Subject) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-80136 | Film No.: 25691401
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 44, TOWER 100, THE TOWERS WINSTON CHURCHILL, PAITILLA PANAMA CITY R1 07196
Business Address
Lazar David E. (Filed by) CIK: 0001932843 (see all company filings)

Type: SCHEDULE 13D